Dose escalation stage of a first-in-class phase I study of the novel oral ERK 1/2 kinase inhibitor BVD-523 (ulixertinib) in patients with advanced solid tumors.

被引：8

作者：

Infante, Jeffrey R.

Janku, Filip

Tolcher, Anthony W.

Patel, Manish R.

Sullivan, Ryan J.

Flaherty, Keith

Carvajal, Richard D.

Varghese, Anna M.

Wong, Deborah Jean Lee

Sznol, Mario

Sosman, Jeffrey Alan

Wang-Gillam, Andrea

Burris, Howard A.

Ribas, Antoni

Patel, Sapna Pradyuman

Welsch, Dean J.

Saha, Saurabh

机构：

[1] Tennessee Oncol, Sarah Cannon Res Inst, Nashville, TN USA

[2] Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Phase Program 1, Houston, TX 77030 USA

[3] START, San Antonio, TX USA

[4] Florida Canc Specialists, Sarah Cannon Res Inst, Sarasota, FL USA

[5] Harvard Univ, Sch Med, Massachusetts Gen Hosp Canc Ctr, Boston, MA USA

[6] Massachusetts Gen Hosp, Boston, MA 02114 USA

[7] Dana Farber Canc Inst, Boston, MA 02115 USA

[8] Columbia Univ Medcl Ctr, New York, NY USA

[9] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA

[10] Univ Calif Los Angeles, Los Angeles, CA USA

[11] Yale Univ, New Haven, CT USA

[12] Vanderbilt Univ Sch Med, Nashville, TN USA

[13] Washington Univ, Div Oncol, St Louis, MO USA

[14] Tennessee Oncol PLLC, Sarah Cannon Res Inst, Nashville, TN USA

[15] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA

[16] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[17] BioMed Valley Discoveries, Kansas City, MO USA

[18] BioMed Valley Discoveries, Wellesley, MA USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期

关键词：

D O I：

10.1200/jco.2015.33.15_suppl.2506

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

2506

引用

页数：1